⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a
very recent recall may be missing. Everything shown is accurate as of the last checked time on this page —
for anything time-critical, confirm with the official sources linked below.
FDAClass III · Drug · Recalled June 10, 2026
Lidocaine HCl Injection recall — Eugia US LLC
Hazard: Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan
Class III: not likely to cause adverse health consequences.
View the official FDA enforcement record (openFDA) ↗
- Official recall ID
- D-0552-2026
- Brand
- Eugia US
- Classification
- Class III
- Units affected
- 168,300 vials
- Recall status
- Ongoing
- Initiated
- Voluntary: Firm initiated
Description
Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02
Affected products
Companies & origin
- Recalling firm location
- East Windsor, NJ, United States
- Firm address
- 279 Princeton Hightstown Rd, 08520-1401
Identifying details (verbatim from the notice)
- Product codes / lots
- Lot, expiry: Lot 3LC26029A, exp Feb-2029; Lot 3LC26031A, exp Mar-2029
- Distribution
- US Nationwide.
- Firm notified the public via
- Letter
- FDA event ID
- 99024
- Recall initiated
- May 18, 2026
- FDA classified
- May 29, 2026
- FDA report date
- June 10, 2026
Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim;
the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.
Report a data error on this page